Table of Content

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 INCLUSIONS & EXCLUSIONS 39
1.4 STUDY SCOPE 40
1.4.1 SEGMENTS CONSIDERED 40
1.4.2 YEARS CONSIDERED 41
1.4.3 CURRENCY CONSIDERED 41
1.5 STAKEHOLDERS 41
1.6 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.1.1 SECONDARY DATA 44
2.1.2 PRIMARY DATA 44
2.2 MARKET SIZE ESTIMATION METHODOLOGY OF AUTOINJECTORS DEVICES 46
2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS 49
2.3.1 INSIGHTS FROM PRIMARY EXPERTS 52
2.3.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 52
2.4 MARKET GROWTH RATE PROJECTIONS 54
2.5 DATA TRIANGULATION 57
2.6 RESEARCH ASSUMPTIONS 58
2.7 RESEARCH LIMITATIONS 58
2.8 RISK ANALYSIS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 67
4.1 AUTOINJECTORS MARKET OVERVIEW 67
4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE AND COUNTRY (2023) 68
4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY ROUTE OF ADMINISTRATION AND COUNTRY (2023) 68
4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET,
BY THERAPY AREA, 2024 VS. 2030 (USD MILLION) 69
4.5 AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2023 69
4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 70
4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
?
5 MARKET OVERVIEW 72
5.1 INTRODUCTION 72
5.2 MARKET DYNAMICS 72
5.2.1 DRIVERS 73
5.2.1.1 Rising prevalence of chronic diseases 73
5.2.1.2 Increasing regulatory approvals for autoinjectors 73
5.2.1.3 High demand for biosimilars and biologics 74
5.2.1.4 Growing adoption of self-administered medicines 75
5.2.1.5 Government support and favorable reimbursement policies 75
5.2.2 RESTRAINTS 76
5.2.2.1 Focus on needle-free drug delivery systems and prevalence
of needle phobia 76
5.2.3 OPPORTUNITIES 76
5.2.3.1 Impending patent expiry of biological molecules 76
5.2.3.2 Launch of technologically advanced autoinjectors 78
5.2.4 CHALLENGES 78
5.2.4.1 Development of autoinjectors for multiple drug viscosities 78
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
5.4 VALUE CHAIN ANALYSIS 79
5.4.1 VALUE CHAIN ANALYSIS: AUTOINJECTOR DEVICE MANUFACTURERS (PLATFORM PROVIDERS) 79
5.4.2 VALUE CHAIN ANALYSIS: AUTOINJECTOR FINISHED FORMULATION MANUFACTURERS 81
5.5 SUPPLY CHAIN ANALYSIS 83
5.6 ECOSYSTEM ANALYSIS 84
5.6.1 AUTOINJECTOR PROVIDERS 85
5.6.2 END USERS 86
5.6.3 REGULATORY BODIES 87
5.7 REGULATORY LANDSCAPE 87
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 87
5.7.1.1 North America 87
5.7.1.2 Europe 88
5.7.1.3 Asia Pacific 88
5.7.1.4 Rest of the World 89
5.7.2 REGULATORY FRAMEWORK 90
5.7.2.1 North America 90
5.7.2.2 Europe 90
5.7.2.3 Asia Pacific 91
5.7.2.4 Rest of the World 91
?
5.8 PORTER’S FIVE FORCES ANALYSIS 91
5.8.1 INTENSITY OF COMPETITIVE RIVALRY 92
5.8.2 BARGAINING POWER OF SUPPLIERS 92
5.8.3 BARGAINING POWER OF BUYERS 93
5.8.4 THREAT OF SUBSTITUTES 93
5.8.5 THREAT OF NEW ENTRANTS 93
5.9 TRADE DATA ANALYSIS 93
5.9.1 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS) 94
5.9.2 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS) 94
5.10 TECHNOLOGY ANALYSIS 95
5.10.1 KEY TECHNOLOGIES 96
5.10.1.1 Injection mechanism technology 96
5.10.1.2 Electronic and connectivity solutions 96
5.10.2 ADJACENT TECHNOLOGIES 97
5.10.2.1 Wearable drug delivery devices 97
5.10.2.2 Implantable drug delivery systems 97
5.10.3 COMPLEMENTARY TECHNOLOGIES 98
5.10.3.1 Power assistance mechanisms 98
5.10.3.2 Advanced needle technology 98
5.11 PATENT ANALYSIS 98
5.11.1 METHODOLOGY 98
5.11.2 PATENTS APPLIED AND GRANTED, 2014–2025 98
5.12 INDICATIVE PRICING ANALYSIS 101
5.12.1 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE 101
5.12.2 AVERAGE SELLING PRICE, BY USAGE 101
5.12.3 INDICATIVE PRICING ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY KEY PLAYER 102
5.12.4 INDICATIVE PRICING ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY REGION 103
5.13 KEY CONFERENCES AND EVENTS, 2025–2026 104
5.14 INVESTMENT AND FUNDING SCENARIO 105
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 106
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 106
5.15.1.1 Key stakeholders in buying process for autoinjector devices 106
5.15.1.2 Key stakeholders in buying process for autoinjector finished formulations 106
5.15.2 KEY BUYING CRITERIA 107
5.15.2.1 Key buying criteria for autoinjector devices 107
5.15.2.2 Key buying criteria for autoinjector finished formulations 109
5.16 IMPACT OF GENERATIVE AI ON AUTOINJECTORS MARKET 110
?
6 AUTOINJECTORS MARKET, BY USAGE 111
6.1 INTRODUCTION 112
6.2 DISPOSABLE AUTOINJECTORS 113
6.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH 113
6.3 REUSABLE AUTOINJECTORS 118
6.3.1 COST-EFFECTIVENESS, VERSATILITY, AND SUSTAINABILITY TO FUEL MARKET GROWTH 118
7 AUTOINJECTORS MARKET, BY TECHNOLOGY 124
7.1 INTRODUCTION 125
7.2 MANUAL AUTOINJECTORS 126
7.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH 126
7.3 AUTOMATIC AUTOINJECTORS 131
7.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH 131
8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION 137
8.1 INTRODUCTION 138
8.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 138
8.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH 138
8.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 142
8.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET 142
9 AUTOINJECTORS MARKET, BY THERAPY AREA 145
9.1 INTRODUCTION 146
9.2 RHEUMATOID ARTHRITIS 147
9.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET 147
9.3 DIABETES 153
9.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND 153
9.4 MULTIPLE SCLEROSIS 158
9.4.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH 158
9.5 ANAPHYLAXIS 164
9.5.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH 164
9.6 OBESITY 169
9.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH 169
9.7 OTHER THERAPY AREAS 174
10 AUTOINJECTORS MARKET, BY VOLUME 180
10.1 INTRODUCTION 181
10.2 UP TO 3ML VOLUME AUTOINJECTORS 181
10.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH 181
10.3 ABOVE 3ML VOLUME AUTOINJECTORS 183
10.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE MARKET 183
11 AUTOINJECTORS MARKET, BY END USER 184
11.1 INTRODUCTION 185
11.2 HOME CARE SETTINGS 185
11.2.1 COST-EFFECTIVENESS AND INCREASED AVAILABILITY OF HOME CARE SUPPORT SERVICES TO PROPEL MARKET GROWTH 185
11.3 HOSPITALS & CLINICS 188
11.3.1 TECHNOLOGICAL ADVANCEMENTS AND AVAILABILITY OF REAL-TIME PATIENT DATA TO SUPPORT MARKET GROWTH 188
11.4 AMBULATORY CARE SETTINGS 190
11.4.1 GROWING DEMAND FOR OUTPATIENT SERVICES TO FUEL MARKET GROWTH 190
12 AUTOINJECTORS MARKET, BY REGION 193
12.1 INTRODUCTION 194
12.2 NORTH AMERICA 195
12.2.1 US 201
12.2.1.1 US to dominate North American autoinjectors market during forecast period 201
12.2.2 CANADA 207
12.2.2.1 Rising geriatric population and increasing prevalence of food allergies to propel market growth 207
12.3 EUROPE 211
12.3.1 GERMANY 217
12.3.1.1 Favorable government initiatives and regulatory trends to aid market growth 217
12.3.2 UK 221
12.3.2.1 High prevalence of allergic conditions and increased incidence of lifestyle diseases to boost market growth 221
12.3.3 FRANCE 225
12.3.3.1 High prevalence of diabetes and favorable reimbursement policies to support market 225
12.3.4 ITALY 228
12.3.4.1 Rising healthcare expenditure and increasing geriatric population to augment market growth 228
?
12.3.5 SPAIN 232
12.3.5.1 Favorable reimbursement scenario and presence of universal health coverage facility to aid market growth 232
12.3.6 REST OF EUROPE 236
12.4 ASIA PACIFIC 240
12.4.1 JAPAN 245
12.4.1.1 Large geriatric population and improved healthcare infrastructure to drive market 245
12.4.2 CHINA 248
12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to fuel market growth 248
12.4.3 INDIA 252
12.4.3.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth 252
12.4.4 SOUTH KOREA 256
12.4.4.1 Increased regulatory approvals and strong clinical pipeline by domestic players to propel market 256
12.4.5 REST OF ASIA PACIFIC 260
12.5 LATIN AMERICA 264
12.5.1 BRAZIL 269
12.5.1.1 Rising adoption of autoinjectors and growing prevalence of chronic diseases to augment market growth 269
12.5.2 REST OF LATIN AMERICA 272
12.6 MIDDLE EAST & AFRICA 276
12.6.1 GCC COUNTRIES 281
12.6.1.1 High healthcare spending capacity and favorable regulatory scenario to drive market 281
12.6.2 REST OF MIDDLE EAST & AFRICA 285
13 COMPETITIVE LANDSCAPE 289
13.1 INTRODUCTION 289
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2021–2025 289
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET 290
13.3 REVENUE ANALYSIS, 2021–2023 292
13.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET 292
13.3.2 REVENUE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 293
13.4 MARKET SHARE ANALYSIS, 2023 293
13.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET 293
13.4.2 MARKET SHARE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 295
?
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 297
13.5.1 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 297
13.5.1.1 Stars 297
13.5.1.2 Emerging leaders 297
13.5.1.3 Pervasive players 298
13.5.1.4 Participants 298
13.5.2 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 299
13.5.2.1 Stars 299
13.5.2.2 Emerging leaders 299
13.5.2.3 Pervasive players 299
13.5.2.4 Participants 299
13.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2023 301
13.5.3.1 Company footprint 301
13.5.3.2 Region footprint 302
13.5.3.3 Usage footprint 304
13.5.3.4 Volume footprint 305
13.5.3.5 Route of administration footprint 306
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 307
13.6.1 PROGRESSIVE COMPANIES 307
13.6.2 RESPONSIVE COMPANIES 307
13.6.3 DYNAMIC COMPANIES 307
13.6.4 STARTING BLOCKS 307
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 309
13.7 COMPANY VALUATION AND FINANCIAL METRICS 310
13.7.1 FINANCIAL METRICS 310
13.7.2 COMPANY VALUATION 311
13.8 BRAND/PRODUCT COMPARISON 312
13.9 COMPETITIVE SCENARIO 313
13.9.1 PRODUCT LAUNCHES AND APPROVALS 313
13.9.2 DEALS 314
13.9.3 EXPANSIONS 315
13.10 DEVICES FOR LARGE-VOLUME FORMULATIONS 316
13.11 DEVICES FOR HIGHLY VISCOUS FORMULATIONS 317
13.12 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET 319
?
14 COMPANY PROFILES 320
14.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET 320
14.1.1 SHL MEDICAL AG 320
14.1.1.1 Business overview 320
14.1.1.2 Products offered 320
14.1.1.3 Recent developments 321
14.1.1.3.1 Product launches 321
14.1.1.3.2 Deals 322
14.1.1.3.3 Expansions 323
14.1.1.4 MnM view 323
14.1.1.4.1 Key strengths 323
14.1.1.4.2 Strategic choices 323
14.1.1.4.3 Weaknesses and competitive threats 323
14.1.2 YPSOMED AG 324
14.1.2.1 Business overview 324
14.1.2.2 Products offered 326
14.1.2.3 Recent developments 327
14.1.2.3.1 Product launches 327
14.1.2.3.2 Deals 327
14.1.2.3.3 Expansions 328
14.1.2.4 MnM view 328
14.1.2.4.1 Key strengths 328
14.1.2.4.2 Strategic choices 328
14.1.2.4.3 Weaknesses and competitive threats 328
14.1.3 BECTON, DICKINSON AND COMPANY (BD) 329
14.1.3.1 Business overview 329
14.1.3.2 Products offered 330
14.1.3.3 Recent developments 331
14.1.3.3.1 Deals 331
14.1.3.3.2 Other developments 331
14.1.3.4 MnM view 332
14.1.3.4.1 Key strengths 332
14.1.3.4.2 Strategic choices 332
14.1.3.4.3 Weaknesses and competitive threats 332
14.1.4 RECIPHARM AB 333
14.1.4.1 Business overview 333
14.1.4.2 Products offered 333
14.1.5 WEST PHARMACEUTICAL SERVICES, INC. 334
14.1.5.1 Business overview 334
14.1.5.2 Products offered 336
14.1.5.3 Recent developments 336
14.1.5.3.1 Expansions 336
14.1.6 PHILLIPS-MEDISIZE 337
14.1.6.1 Business overview 337
14.1.6.2 Products offered 337
14.1.6.3 Recent developments 338
14.1.6.3.1 Product launches 338
14.1.7 HALOZYME, INC. 339
14.1.7.1 Business overview 339
14.1.7.2 Products offered 341
14.1.8 OWEN MUMFORD LTD. 342
14.1.8.1 Business overview 342
14.1.8.2 Products offered 342
14.1.8.3 Recent developments 343
14.1.8.3.1 Product launches 343
14.1.8.3.2 Deals 343
14.1.8.3.3 Expansions 343
14.2 KEY PLAYERS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 344
14.2.1 ABBVIE INC. 344
14.2.1.1 Business overview 344
14.2.1.2 Products offered 345
14.2.1.3 Recent developments 346
14.2.1.3.1 Product launches and approvals 346
14.2.2 ELI LILLY AND COMPANY 347
14.2.2.1 Business overview 347
14.2.2.2 Products offered 349
14.2.2.3 Recent developments 350
14.2.2.3.1 Product approvals 350
14.2.2.3.2 Deals 350
14.2.3 AMGEN INC. 351
14.2.3.1 Business overview 351
14.2.3.2 Products offered 353
14.2.3.3 Recent developments 353
14.2.3.3.1 Product launches 353
14.2.4 NOVO NORDISK A/S 354
14.2.4.1 Business overview 354
14.2.4.2 Products offered 355
14.2.4.3 Recent developments 356
14.2.4.3.1 Product approvals 356
14.2.4.3.2 Deals 356
14.2.4.3.3 Expansions 357
14.2.4.3.4 Other developments 357
?
14.2.5 JOHNSON & JOHNSON SERVICES, INC. 358
14.2.5.1 Business overview 358
14.2.5.2 Products offered 360
14.2.6 SANOFI 361
14.2.6.1 Business overview 361
14.2.6.2 Products offered 362
14.2.7 GSK PLC 363
14.2.7.1 Business overview 363
14.2.7.2 Products offered 364
14.2.7.3 Recent developments 365
14.2.7.3.1 Product approvals 365
14.3 OTHER PLAYERS 366
14.3.1 GERRESHEIMER AG 366
14.3.2 HASELMEIER 367
14.3.3 SMC LTD 368
14.3.4 KALEO, INC. 369
14.3.5 SOLTEAM INCORPORATION CO., LTD. 370
14.3.6 ELCAM DRUG DELIVERY DEVICES 371
14.3.7 CROSSJECT 372
14.3.8 JABIL INC. 372
14.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC 373
14.3.10 MIDAS PHARMA GMBH 373
15 APPENDIX 374
15.1 DISCUSSION GUIDE 374
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 380
15.3 CUSTOMIZATION OPTIONS 382
15.4 RELATED REPORTS 382
15.5 AUTHOR DETAILS 383



List of Figures

FIGURE 1 AUTOINJECTORS MARKET: SEGMENTS CONSIDERED 40
FIGURE 2 AUTOINJECTORS MARKET: YEARS CONSIDERED 41
FIGURE 3 AUTOINJECTORS MARKET: RESEARCH DESIGN 43
FIGURE 4 BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS): AUTOINJECTORS MARKET 45
FIGURE 5 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH) 46
FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES:
REVENUE SHARE ANALYSIS 47
FIGURE 7 ILLUSTRATIVE EXAMPLE OF YPSOMED AG: REVENUE SHARE ANALYSIS (2023) 47
FIGURE 8 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH) 49
FIGURE 9 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: REVENUE SHARE ANALYSIS 50
FIGURE 10 ILLUSTRATIVE EXAMPLE OF ABBVIE INC.: REVENUE SHARE ANALYSIS (2023) 50
FIGURE 11 AUTOINJECTORS MARKET: MARKET VALIDATION FROM PRIMARY EXPERTS 52
FIGURE 12 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 52
FIGURE 13 AUTOINJECTOR DEVICES MARKET SIZE ESTIMATION 53
FIGURE 14 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS (2024–2030) 55
FIGURE 15 AUTOINJECTOR FINISHED FORMULATIONS MARKET:
CAGR PROJECTIONS (2024–2030) 55
FIGURE 16 DATA TRIANGULATION METHODOLOGY 57
FIGURE 17 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024 VS. 2030 (USD MILLION) 60
FIGURE 18 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024 VS. 2030 (MILLION UNITS) 61
FIGURE 19 AUTOINJECTOR FINISHED FORMULATIONS MARKET BY USAGE, 2024 VS. 2030 (USD BILLION) 61
FIGURE 20 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION 2024 VS. 2030 (USD MILLION) 62
FIGURE 21 AUTOINJECTOR FINISHED FORMULATIONS MARKET BY ROUTE OF ADMINISTRATION, 2024 VS. 2030 (USD BILLION) 63
FIGURE 22 AUTOINJECTOR DEVICES MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 63
FIGURE 23 AUTOINJECTOR FINISHED FORMULATIONS MARKET BY END USER, 2024 VS. 2030 (USD BILLION) 64
FIGURE 24 AUTOINJECTOR DEVICES MARKET: REGIONAL SNAPSHOT 65
FIGURE 25 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REGIONAL SNAPSHOT 66
FIGURE 26 INCREASING REGULATORY APPROVALS FOR FINISHED FORMULATION DRUGS
TO PROPEL MARKET GROWTH 67
FIGURE 27 US AND DISPOSABLE AUTOINJECTORS DOMINATED MARKET IN 2023 68
FIGURE 28 US AND SUBCUTANEOUS ROUTE OF ADMINISTRATION COMMANDED LARGER MARKET SHARE IN 2023 68
FIGURE 29 RHEUMATOID ARTHRITIS TO DOMINATE MARKET DURING FORECAST PERIOD 69
FIGURE 30 MANUAL AUTOINJECTORS ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 69
FIGURE 31 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030 70
?
FIGURE 32 ASIA PACIFIC TO COMMAND HIGHEST CAGR DURING STUDY PERIOD 71
FIGURE 33 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES 72
FIGURE 34 REVENUE SHIFT AND POCKETS FOR AUTOINJECTOR PROVIDERS 79
FIGURE 35 AUTOINJECTOR DEVICES MARKET: VALUE CHAIN ANALYSIS 80
FIGURE 36 AUTOINJECTOR FINISHED FORMULATIONS MARKET: VALUE CHAIN ANALYSIS 82
FIGURE 37 AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS 84
FIGURE 38 AUTOINJECTORS MARKET: ECOSYSTEM MAP 84
FIGURE 39 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 92
FIGURE 40 PATENT APPLICATIONS IN AUTOINJECTORS MARKET JANUARY 2014–JANUARY 2025 99
FIGURE 41 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE (2021–2023) 101
FIGURE 42 AVERAGE SELLING PRICE TREND, BY USAGE (2021–2023) 101
FIGURE 43 KEY STAKEHOLDERS IN BUYING PROCESS FOR PHARMACEUTICAL COMPANIES (AUTOINJECTOR DEVICES) 106
FIGURE 44 KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS (AUTOINJECTOR FINISHED FORMULATIONS) 107
FIGURE 45 KEY BUYING CRITERIA FOR AUTOINJECTOR DEVICES AMONG END USERS 108
FIGURE 46 KEY BUYING CRITERIA FOR AUTOINJECTOR FINISHED FORMULATIONS
AMONG END USERS 109
FIGURE 47 AUTOINJECTORS MARKET: IMPACT OF GEN AI 110
FIGURE 48 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT (2023) 195
FIGURE 49 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET
SNAPSHOT (2023) 196
FIGURE 50 EUROPE: AUTOINJECTOR DEVICES MARKET SNAPSHOT 211
FIGURE 51 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET SNAPSHOT 212
FIGURE 52 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET
(2021–2023) 292
FIGURE 53 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET (2021–2023) 293
FIGURE 54 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES
MARKET (2023) 294
FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET (2023) 296
FIGURE 56 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 298
FIGURE 57 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 300
FIGURE 58 AUTOINJECTOR DEVICES MARKET: COMPANY FOOTPRINT 301
FIGURE 59 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY FOOTPRINT 302
FIGURE 60 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 308
FIGURE 61 EV/EBITDA OF KEY VENDORS 310
FIGURE 62 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 311
?
FIGURE 63 AUTOINJECTOR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 312
FIGURE 64 YPSOMED AG: COMPANY SNAPSHOT (2023) 325
FIGURE 65 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2024) 330
FIGURE 66 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2023) 335
FIGURE 67 HALOZYME, INC.: COMPANY SNAPSHOT (2023) 340
FIGURE 68 ABBVIE INC.: COMPANY SNAPSHOT (2023) 345
FIGURE 69 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023) 348
FIGURE 70 AMGEN INC.: COMPANY SNAPSHOT (2023) 352
FIGURE 71 NOVO NORDISK A/S: COMPANY SNAPSHOT (2023) 355
FIGURE 72 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023) 359
FIGURE 73 SANOFI: COMPANY SNAPSHOT (2023) 362
FIGURE 74 GSK PLC: COMPANY SNAPSHOT (2023) 364

List of Tables

TABLE 1 AUTOINJECTORS MARKET: INCLUSIONS & EXCLUSIONS 39
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON AUTOINJECTORS MARKET 56
TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE 2020–2024 74
TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS 77
TABLE 5 LIST OF KEY AUTOINJECTOR DEVICE PROVIDERS 85
TABLE 6 LIST OF KEY AUTOINJECTOR FINISHED FORMULATION PRODUCT PROVIDERS 86
TABLE 7 LIST OF KEY END USERS 86
TABLE 8 LIST OF KEY REGULATORY BODIES 87
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 87
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 88
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 88
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 89
TABLE 13 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 91
TABLE 14 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS) 2021–2023 (USD MILLION) 94
TABLE 15 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS) 2021–2023 (USD MILLION) 94
TABLE 16 LIST OF ADVANTAGES AND DISADVANTAGES OF AUTOINJECTOR TECHNOLOGIES 95
TABLE 17 PATENTS FILED, 2014–2024 98
TABLE 18 INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024 99
TABLE 19 INDICATIVE PRICING OF FINISHED FORMULATION PRODUCTS BY KEY PLAYER, 2023 102
TABLE 20 INDICATIVE PRICING ANALYSIS OF THERAPY AREAS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY REGION, 2023 103
TABLE 21 AUTOINJECTORS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 104
TABLE 22 AUTOINJECTOR DEVICES MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 106
TABLE 23 AUTOINJECTOR FINISHED FORMULATIONS MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 107
TABLE 24 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 112
TABLE 25 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (MILLION UNITS) 112
TABLE 26 AUTOINJECTOR FINISHED FORMULATIONS MARKET BY USAGE, 2022–2030 (USD MILLION) 112
TABLE 27 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (USD MILLION) 113
TABLE 28 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (MILLION UNITS) 113
TABLE 29 NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 114
TABLE 30 EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 114
TABLE 31 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 115
TABLE 32 LATIN AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 115
TABLE 33 MIDDLE EAST & AFRICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET BY REGION, 2022–2030 (USD MILLION) 115
TABLE 34 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET BY REGION, 2022–2030 (USD MILLION) 116
TABLE 35 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116
TABLE 36 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 37 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 117
TABLE 38 LATIN AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 118
TABLE 39 MIDDLE EAST & AFRICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 118
TABLE 40 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (USD MILLION) 119
TABLE 41 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (MILLION UNITS) 119
TABLE 42 NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 119
TABLE 43 EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY 2022–2030 (USD MILLION) 120
TABLE 44 ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 120
TABLE 45 LATIN AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 121
TABLE 46 MIDDLE EAST & AFRICA: REUSABLE AUTOINJECTOR DEVICES MARKET BY REGION, 2022–2030 (USD MILLION) 121
TABLE 47 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET BY REGION, 2022–2030 (USD MILLION) 121
TABLE 48 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 49 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 50 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 51 LATIN AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 52 MIDDLE EAST & AFRICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 123
TABLE 53 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 125
TABLE 54 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022–2030 (MILLION UNITS) 125
TABLE 55 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 125
TABLE 56 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (USD MILLION) 126
TABLE 57 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (MILLION UNITS) 127
TABLE 58 NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 59 EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY 2022–2030 (USD MILLION) 127
TABLE 60 ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 128
TABLE 61 LATIN AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 128
TABLE 62 MIDDLE EAST & AFRICA: MANUAL AUTOINJECTOR DEVICES MARKET BY REGION, 2022–2030 (USD MILLION) 128
TABLE 63 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET BY REGION, 2022–2030 (USD MILLION) 129
TABLE 64 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 129
TABLE 65 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 66 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 67 LATIN AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 131
TABLE 68 MIDDLE EAST & AFRICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 131
TABLE 69 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (USD MILLION) 132
TABLE 70 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (MILLION UNITS) 132
TABLE 71 NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 133
TABLE 72 EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 133
TABLE 73 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 134
TABLE 74 LATIN AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET BY COUNTRY, 2022–2030 (USD MILLION) 134
TABLE 75 MIDDLE EAST & AFRICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET BY REGION, 2022–2030 (USD MILLION) 134
TABLE 76 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET BY REGION, 2022–2030 (USD MILLION) 135
TABLE 77 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 78 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 79 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 80 LATIN AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 81 MIDDLE EAST & AFRICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022–2030 (USD MILLION) 136
TABLE 82 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION 2022–2030 (USD MILLION) 138
TABLE 83 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION 2022–2030 (MILLION UNITS) 138
TABLE 84 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2030 (USD MILLION) 139
TABLE 85 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2030 (MILLION UNITS) 140
TABLE 86 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 87 EUROPE: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 88 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 141
TABLE 89 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 141
TABLE 90 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2030 (USD MILLION) 141
TABLE 91 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 142
TABLE 92 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2022–2030 (MILLION UNITS) 143
TABLE 93 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 94 EUROPE: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 95 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 96 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 97 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2022–2030 (USD MILLION) 144
TABLE 98 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022–2030 (USD MILLION) 146
TABLE 99 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA 2022–2030 (MILLION UNITS) 146
TABLE 100 AUTOINJECTOR FINISHED FORMULATIONS MARKET BY THERAPY AREA, 2022–2030 (USD MILLION) 147
TABLE 101 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (USD MILLION) 148
TABLE 102 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (MILLION UNITS) 148
TABLE 103 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 149
TABLE 104 EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS BY COUNTRY, 2022–2030 (USD MILLION) 149
TABLE 105 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 106 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 107 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (USD MILLION) 150
TABLE 108 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (USD MILLION) 151
TABLE 109 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 151
TABLE 110 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 111 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 112 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022–2030 (USD MILLION) 153
TABLE 113 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022–2030 (USD MILLION) 153
TABLE 114 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION 2022–2030 (USD MILLION) 154
TABLE 115 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION 2022–2030 (MILLION UNITS) 154
TABLE 116 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES BY COUNTRY, 2022–2030 (USD MILLION) 155
TABLE 117 EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES BY COUNTRY, 2022–2030 (USD MILLION) 155
TABLE 118 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES BY COUNTRY, 2022–2030 (USD MILLION) 155
TABLE 119 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES BY COUNTRY, 2022–2030 (USD MILLION) 156
TABLE 120 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES BY REGION, 2022–2030 (USD MILLION) 156
TABLE 121 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES BY REGION, 2022–2030 (USD MILLION) 156
TABLE 122 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 123 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 124 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 125 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022–2030 (USD MILLION) 158
TABLE 126 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2022–2030 (USD MILLION) 158
TABLE 127 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS BY REGION, 2022–2030 (USD MILLION) 159
TABLE 128 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS BY REGION, 2022–2030 (MILLION UNITS) 159
TABLE 129 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS BY COUNTRY, 2022–2030 (USD MILLION) 159
TABLE 130 EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS BY COUNTRY, 2022–2030 (USD MILLION) 160
TABLE 131 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS BY COUNTRY, 2022–2030 (USD MILLION) 160
TABLE 132 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS BY COUNTRY, 2022–2030 (USD MILLION) 161
TABLE 133 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022–2030 (USD MILLION) 161
TABLE 134 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS BY REGION, 2022–2030 (USD MILLION) 161
TABLE 135 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022–2030 (USD MILLION) 162
TABLE 136 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022–2030 (USD MILLION) 162
TABLE 137 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022–2030 (USD MILLION) 163
TABLE 138 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022–2030 (USD MILLION) 163
TABLE 139 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022–2030 (USD MILLION) 163
TABLE 140 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS BY REGION, 2022–2030 (USD MILLION) 164
TABLE 141 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS BY REGION, 2022–2030 (MILLION UNITS) 165
TABLE 142 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS BY COUNTRY, 2022–2030 (USD MILLION) 165
TABLE 143 EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS BY COUNTRY, 2022–2030 (USD MILLION) 165
TABLE 144 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS BY COUNTRY, 2022–2030 (USD MILLION) 166
TABLE 145 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS BY COUNTRY, 2022–2030 (USD MILLION) 166
TABLE 146 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS BY REGION, 2022–2030 (USD MILLION) 166
TABLE 147 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS BY REGION, 2022–2030 (USD MILLION) 167
TABLE 148 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 167
TABLE 149 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 167
TABLE 150 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 168
TABLE 151 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022–2030 (USD MILLION) 168
TABLE 152 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2022–2030 (USD MILLION) 168
TABLE 153 AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION 2022–2030 (USD MILLION) 169
TABLE 154 AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION 2022–2030 (MILLION UNITS) 170
TABLE 155 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY BY COUNTRY, 2022–2030 (USD MILLION) 170
TABLE 156 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OBESITY BY COUNTRY, 2022–2030 (USD MILLION) 170
TABLE 157 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OBESITY BY COUNTRY, 2022–2030 (USD MILLION) 171
TABLE 158 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY BY COUNTRY, 2022–2030 (USD MILLION) 171
TABLE 159 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY BY REGION, 2022–2030 (USD MILLION) 171
TABLE 160 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY BY REGION, 2022–2030 (USD MILLION) 172
TABLE 161 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022–2030 (USD MILLION) 172
TABLE 162 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY BY COUNTRY, 2022–2030 (USD MILLION) 173
TABLE 163 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY BY COUNTRY, 2022–2030 (USD MILLION) 173
TABLE 164 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022–2030 (USD MILLION) 174
TABLE 165 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY REGION, 2022–2030 (USD MILLION) 174
TABLE 166 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS BY REGION, 2022–2030 (USD MILLION) 175
TABLE 167 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS BY REGION, 2022–2030 (MILLION UNITS) 175
TABLE 168 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 175
TABLE 169 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS BY COUNTRY, 2022–2030 (USD MILLION) 176
TABLE 170 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS BY COUNTRY, 2022–2030 (USD MILLION) 176
TABLE 171 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 177
TABLE 172 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2030 (USD MILLION) 177
TABLE 173 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2030 (USD MILLION) 177
TABLE 174 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 178
TABLE 175 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 178
TABLE 176 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 178
TABLE 177 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2030 (USD MILLION) 179
TABLE 178 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2030 (USD MILLION) 179
TABLE 179 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022–2030 (USD MILLION) 181
TABLE 180 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022–2030 (MILLION UNITS) 181
TABLE 181 UP TO 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (USD MILLION) 182
TABLE 182 UP TO 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (MILLION UNITS) 182
TABLE 183 ABOVE 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (USD MILLION) 183
TABLE 184 ABOVE 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION 2022–2030 (MILLION UNITS) 183
TABLE 185 AUTOINJECTOR DEVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 185
TABLE 186 AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS BY REGION, 2022–2030 (USD MILLION) 186
TABLE 187 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 186
TABLE 188 EUROPE: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS BY COUNTRY, 2022–2030 (USD MILLION) 186
TABLE 189 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS BY COUNTRY, 2022–2030 (USD MILLION) 187
TABLE 190 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS BY COUNTRY, 2022–2030 (USD MILLION) 187
TABLE 191 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION) 187
TABLE 192 AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS BY REGION, 2022–2030 (USD MILLION) 188
TABLE 193 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2022–2030 (USD MILLION) 188
TABLE 194 EUROPE: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2022–2030 (USD MILLION) 189
TABLE 195 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2022–2030 (USD MILLION) 189
TABLE 196 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2022–2030 (USD MILLION) 189
TABLE 197 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2030 (USD MILLION) 190
TABLE 198 AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS BY REGION, 2022–2030 (USD MILLION) 191
TABLE 199 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 191
TABLE 200 EUROPE: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS BY COUNTRY, 2022–2030 (USD MILLION) 191
TABLE 201 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 192
TABLE 202 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 192
TABLE 203 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION) 192
TABLE 204 AUTOINJECTOR DEVICES MARKET, BY REGION, 2022–2030 (USD MILLION) 194
TABLE 205 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION 2022–2030 (USD MILLION) 194
TABLE 206 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY 2022–2030 (USD MILLION) 197
TABLE 207 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE 2022–2030 (USD MILLION) 197
TABLE 208 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET BY TECHNOLOGY, 2022–2030 (USD MILLION) 197
TABLE 209 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 198
TABLE 210 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET BY THERAPY AREA, 2022–2030 (USD MILLION) 198
TABLE 211 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET BY VOLUME, 2022–2030 (USD MILLION) 198
TABLE 212 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET BY END USER, 2022–2030 (USD MILLION) 199
TABLE 213 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 199
TABLE 214 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY USAGE, 2022–2030 (USD MILLION) 199
TABLE 215 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY TECHNOLOGY, 2022–2030 (USD MILLION) 200
TABLE 216 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 200
TABLE 217 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY THERAPY AREA, 2022–2030 (USD MILLION) 200
TABLE 218 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY VOLUME, 2022–2030 (USD MILLION) 201
TABLE 219 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY END USER, 2022–2030 (USD MILLION) 201
TABLE 220 AUTOINJECTORS APPROVED BY US FDA, 2018–2024 203
TABLE 221 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022–2030 (USD MILLION) 203
TABLE 222 US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 204
TABLE 223 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION 2022–2030 (USD MILLION) 204
TABLE 224 US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA 2022–2030 (USD MILLION) 204
TABLE 225 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022–2030 (USD MILLION) 205
TABLE 226 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY USAGE, 2022–2030 (USD MILLION) 205
TABLE 227 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY TECHNOLOGY, 2022–2030 (USD MILLION) 205
TABLE 228 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 206
TABLE 229 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY THERAPY AREA, 2022–2030 (USD MILLION) 206
TABLE 230 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY END USER, 2022–2030 (USD MILLION) 206
TABLE 231 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE 2022–2030 (USD MILLION) 207
TABLE 232 CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 208
TABLE 233 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030 (USD MILLION) 208
TABLE 234 CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA 2022–2030 (USD MILLION) 208
TABLE 235 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER 2022–2030 (USD MILLION) 209
TABLE 236 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY USAGE, 2022–2030 (USD MILLION) 209
TABLE 237 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET BY TECHNOLOGY, 2022–2030 (USD MILLION)